Better drug utilization - Reduced costs

New formulations, particularly those tested for efficacy in clinical development programs for inhalation therapy, are often extremely expensive to manufacture. AKITA®'s unbeatable "drug use efficiency" guarantees minimal drug consumption, a factor that subsequently reduces clinical study costs.

AKITA2 APIXNEBTM deposits approximately 70% of the medication measured in the nebulizer into the lungs, whereas conventional inhalation systems only achieve a deposition rate of 5-15% - actual clinical data are proving this. [PDF]

Reference: Brand et al 2009: Lung deposition of inhaled α-1-proteinase inhibitor in cystic fibrosis and α-1-antitrypsin deficiency. European Respiratory Journal 2009: 34: 354-360.

AKITA® JET - Superior "drug use efficiency"

FAVORITE technology actively controls optimal breathing, a factor which ensures that AKITA® JET utilizes drugs in an efficient and effective manner. Favorable data on AKITA® JET's "Drug Use Efficiency" in comparison with systems without FAVORITE inhalation technology was recently presented in a series of posters at the 2010 congress of the European Respiratory Society (ERS) in Barcelona, Spain. [PDF]

Reference: Kroneberg et al. 2010: The effect of different nebulizer systems in inhaled tobramycin; Posterpresentation ERS, Barcelona, Spain, 18.-23- Sept. 2010 - Abstract ID 3505, Presentation ID E3505.

  • AKITA2 APIXNEBTM in AATD and CF patients -
    70% efficiency in lung deposition
    [ERJ publication]